AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation Science
BenzothiepinsBenzazepines2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineReceptors, Dopamine D1Dopamine AntagonistsBenzocycloheptenesDopamine AgonistsReceptors, Dopamine D2QuinpiroleDihydroxycholecalciferolsReceptors, DopamineHydroxycholecalciferolsDopamineRicinoleic AcidsCalcitriolTaurodeoxycholic AcidBehavior, AnimalLeukotriene A4Dose-Response Relationship, DrugRats, Sprague-DawleyGlycodeoxycholic AcidDeoxycholic AcidChenodeoxycholic AcidArachidonate LipoxygenasesHydroxylationTaurocholic AcidReceptors, CalcitriolStereoisomerismChromatography, Thin LayerChromatography, High Pressure LiquidHydro-LyasesHydroxy AcidsChromatography, GasCatecholsMass SpectrometryMolecular StructureUrsodeoxycholic AcidStructure-Activity RelationshipCholic AcidsGas Chromatography-Mass SpectrometryIsoleucineBileLipoxygenaseBiotransformationIntestinal AbsorptionKineticsPhenyl EthersMagnetic Resonance SpectroscopyArachidonic AcidsMixed Function OxygenasesVitamin D DeficiencyTaurineIntestine, SmallOxidation-ReductionBiological Transport, ActiveVitamin DCytochrome P-450 Enzyme SystemMicrosomes, LiverLiverCalciumFatty AcidsSpecies SpecificityCholesterol4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amineMolecular Sequence DataCells, Cultured3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl esterTime FactorsPhenylacetates
MethylDopamineReceptor-preferr1989PharmacologyRatsCompoundsDepartmentResultsBenefits
Methyl1
  • In this study we investigated whether 6-chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) has improvements on cognitive dysfunction. (nih.gov)
Dopamine3
  • The five types of dopamine (DA) receptor subtypes have been grouped into two families, the D(1)-like (D(1) and D(5) receptors) and D(2)-like (D(2), D(3), and D(4) receptors). (nih.gov)
  • The effect of the specific dopamine D-1 receptor agonist Fenoldopam on pulsatile gonadotropin secretion and prolactin (PRL) secretion was investigated in normal women. (nih.gov)
  • Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. (nih.gov)
Receptor-preferr1
  • To investigate this issue, rats were trained using standard operant drug discrimination procedures to discriminate 0.10 mg/kg of the putatively D(3) receptor-preferring agonist R(+)-7-hydroxy-N,N,-di-n-propyl-2-aminotetralin (7-OH-DPAT) from saline. (nih.gov)
19891
Pharmacology1
  • 3 Department of Pharmacology, School of Pharmacy, Nantong University. (nih.gov)
Rats1
  • METHODS@#Male Sprague-Dawley rats were equally divided into 3 groups using a random number table: the control group, the OIPN group, and the EA (OIPN + EA) group, with 10 rats in each. (bvsalud.org)
Compounds1
  • These results suggest both pre- and postsynaptic actions of 7-OH-DPAT along with a lack of specificity of the various pharmacological compounds for the D(3) receptor. (nih.gov)
Department2
  • 1 Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen, Denmark. (nih.gov)
  • 1 Department of Pharmacy, The Second Affiliated Hospital of Nantong University. (nih.gov)
Results1
  • The results suggest that D-1 receptor stimulation does not affect pulsatile gonadotropin secretion but increases the pituitary responsiveness to GnRH. (nih.gov)
Benefits1
  • As a general overview, some examples of the possible benefits of drug combinations include: (1) Enhanced euphoria, e.g. see speedball which is massively euphoric but also very dangerous, (2) reduced psychological discomfort (e.g. anxiolytics with psychedelics), (3) uniquely interesting effects, e.g. (qualiacomputing.com)